Publication | Closed Access

Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial

First-line TherapyUrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorAnti-cancer AgentCancer TreatmentPhase 2OncologyRadiation Oncology